and a repeat study in 2014 reported that 3 of 7 devices still failed performance criteria. 12 Nevertheless, there are 2 POC techniques, the Afinion boronate affinity method and the DCA Vantage immunoturbidometric procedure, which have consistently performed well on comparison testing. [13] [14] [15] [16] These 2 techniques have also been compared to one another. In a study of 700 pediatric patients, each subject's HbA1C was measured locally using the Afinion and DCA devices, and by a central laboratory (University of Minnesota) using a Tosoh high-performance liquid chromatography (HPLC) method. In the patient samples measured at the 7 clinic sites, the Afinion generated higher A1C results than the HPLC (mean difference = +0.15, P < .001), while the DCA produced lower values (mean difference = -0.19, P < .001). These differences were felt to be clinically insignificant. Yet, even with these 2 well validated POC devices, there have been criticisms including lot to lot variation and nonlinearity of results. 9, [17] [18] [19] There have been continued efforts to standardize the HbA1c assay. Early studies showed that the many methods used to measure HbA1c produced disparate results. 20 The National Glycohemoglobin Standardization Program (NGSP) was implemented in 1996 to standardize HbA1c results to those of the Diabetes Control and Complications Trial/ United Kingdom Prospective Diabetes Study (DCCT/ UKPDS), which used an HPLC technique as the gold standard assay. 21 This program is used to certify manufacturers of HbA1c methods as traceable to the DCCT. 22 For HbA1c standardization, a network of reference laboratories is calibrated to the DCCT Reference values. The NGSP network consists of the central primary reference laboratory (CPRL), 3 primary reference laboratories (PRLs), and 7 secondary reference laboratories (SRLs). PRLs and SRLs are located both in Europe, Japan, and the United States. 23 The CPRL method is the DCCT/EDIC (Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications) Bio-Rex 70 HPLC reference method. The PRLs, which use the same method as the CPRL, function as backup laboratories. The SRLs use a variety of commercial methods based on ion-exchange HPLC immunoassay, boronate-affinity HPLC, or capillary electrophoresis. NGSP compliant network laboratories are monitored monthly by using 10 pooled whole blood samples frozen at -70 0 C spanning the range of 4%-10%. These calibrators are compared monthly to each other and to the original DCCT reference. This reference has been shown to be consistent over 30 years using overlapping frozen hemolysates. 24 To pass the NGSP monitoring exercise, the standard deviation of the difference between sample replicates must not exceed 0.229% HbA1c. In addition, the mean of the differences between an individual network laboratory and the CPRL must not exceed 0.35% HbA1c. The function of the NGSP is to standardize HbA1c and ensure that results from clinical laboratories match those of the DCCT. The NGSP assists manufacturers with calibrating their assays, has a formal certification process and monitors performance of HbA1c testing in the field via the College of American Pathologists (CAP) survey which uses fresh whole blood. This program has been successful in reducing variability in HbA1c results.
In the clinical setting, the value of HbA1c is in comparing the degree of cumulative hyperglycemia experienced by the individual patient at serial points in time to guide changes in the therapeutic regimen. It is essential to have comparability of values over extended time periods. The use of POC devices to measure HbA1c is widespread in diabetes clinics, so we need to know how well POC devices perform over the long-term course of treatment. We assessed the reliability of 2 POC HbA1c assay techniques in a real world clinic setting over a 3-year period, comparing the results to 2 central laboratory techniques.
Materials and Methods
We compared results obtained with the 2 most commonly used POC techniques, the Axis-Shield Afinion hemoglobin A1c device (Afinion) boronate affinity assay and the DCA Vantage immunoturbidometric procedure (DCA) on unselected samples from patients participating in various clinical research protocols. All patients agreed to participate in these protocols and provided signed informed consent. HbA1c determinations in these protocols were performed by large central labs typically using either the Tosoh G8 HPLC Analyzer or the Bio-Rad Variant II, both ion exchange HPLC techniques. The central lab samples were obtained from 4 ml venous blood samples. Microliter volumes were withdrawn from these samples and assayed using both POC techniques. The use of these small blood samples was approved by the Creighton Institutional Review Board and did not require separate additional consent. All HbA1c samples were subjected to simultaneous assay with the Afinion and the DCA procedures as well as the central lab technique utilized for the various protocols. Results throughout are expressed as percentage HbA1c.
Axis Shield Afinion Hemoglobin A1c Measurement
Afinion™ HbA1c is a fully automated boronate affinity assay for the determination of the percentage of hemoglobin A1c in human whole blood. 25 A 1.5 µl blood sample is introduced into the Test Cartridge which is placed in the chamber of the Afinion AS100 Analyzer where it is automatically diluted and mixed with a solution which lyses erythrocytes, releasing hemoglobin. This sample mixture is transferred to a blue labeled boronic acid conjugate, which binds to the cisdiols of glycated hemoglobin. This reaction mixture is soaked through a filter membrane which collects conjugatebound and unbound hemoglobin (glycated and nonglycated hemoglobin). Excess conjugate is removed with a washing reagent. The Analyzer reflectance meter separately measures the blue (glycated hemoglobin) and the red (total hemoglobin) color intensities. The ratio of the 2 color intensities is proportional to the percentage of HbA1c in the sample.
DCA Vantage POC HbA1c Technique
The DCA Vantage, unlike the Afinion method, is immunoassay based. 26 A 1 µl whole blood sample is added to the reagent cartridge which is inserted into the DCA Vantage™ Analyzer. Within the cartridge, potassium ferricyanide oxidizes hemoglobin in the sample to methemoglobin which complexes with thiocyanate to form thiocyanmethemoglobin. The Analyzer spectrophotometer measures the intensity of the light transmitted by thiocyanmethemoglobin. The extent of color development at 531 nm is proportional to the concentration of total hemoglobin in the sample. A synthetic polymer containing multiple copies of the immunoreactive portion of HbA1c is used to cause agglutination of latex coated with HbA1c specific mouse monoclonal antibody. This agglutination causes increased scattering of light, measured as an increase in absorbance at 531 nm. HbA1c in whole blood specimens competes for the limited number of antibody-latex binding sites causing an inhibition of agglutination which is measured as a decrease in absorbance. The HbA1c concentration is then quantified using a calibration curve of absorbance versus HbA1c concentration.
The Tosoh Automated Glycohemoglobin Analyzer HLC-723G8
This is an HPLC technique using nonporous ion exchange. 27 The analyzer dilutes the whole blood specimen (3 uL) and then injects a small volume of this specimen onto the TSKgel G8 Variant HSi column. Separation is achieved by utilizing differences in ionic interactions between the cation exchange group on the column resin surface and the hemoglobin components. The hemoglobin fractions (designated as A1a, A1b, F, LA1c+, SA1c, A0, and H-V0, H-V1, HV2) are subsequently removed from the column by performing a step-wise elution using varied salt concentrations in the Variant Elution Buffers. The separated hemoglobin components pass through an LED photometer flow cell which measures changes in absorbance at 415 nm. The analyzer integrates each peak. The total area of the A1c peak is divided by the sum of the total areas of all peaks to compute the HbA1c percentage.
The Bio-Rad Variant II Turbo Hemoglobin A1c
The Bio-Rad Variant II likewise utilizes an ion-exchange HPLC. 28 The samples are automatically diluted and injected into the analytical cartridge. The Variant II Turbo Chromatographic Station (VCS) dual pumps deliver a programmed buffer gradient of increasing ionic strength to the cartridge, where the hemoglobins are separated based on their ionic interactions with the cartridge material similar to the Tosoh procedure. The absorbance at 415 nm is measured and the peak ratio of HbA1c to total Hemoglobin is calculated.
POC Control Procedures
The Afinion and DCA procedures are packaged in specific kits, manufactured in lots, with control samples provided. These control samples have been measured by the manufacturer, and average values with permissible upper and lower bounds are provided. Controls were run in our lab in replicate for each lot. In addition, our laboratory participated in the Lab Advantage Program of the American Proficiency Institute. 29 This program provides control samples as "unknowns." These unknowns are typically samples with either a high or a low value. Different samples are provided for each analytic technique. We assay these unknowns in replicate and send the results for evaluation to the Program which analyzes the results provided by many laboratories and reports a mean and a permissible range for each separate technique. The College of American Pathologists (CAP) carries out surveys of NGSP certified techniques using reference standards as part of the NGSP protocol at the reference lab network. The difference in assay values from the reference values is termed the "bias" of the assay. The bias calculation is performed for 3 levels of pooled fresh blood samples: a low, midrange and high. The CAP survey analysis is performed twice annually with 5 different sample groups.
Results
Our results for control samples for the 2 POC techniques were well within the established permissible deviation for each assay (Figure 1) , and results submitted to the American Proficiency quality assurance program were in range at all times in the 3-year course of our study ( Figure 2 ). There was a high correlation between values obtained on the DCA Vantage and the Afinion devices (Figure 3) , and the 2 POC techniques showed high correlation with the 2 central lab techniques (Figure 4 ). Despite the high correlations, there were clear differences in the values obtained on individual samples with the 2 POC devices, and the values also differed from the central lab techniques. Furthermore, these differences were quite variable over time. The Biorad values varied from 0.1 to 0.4% higher than the Afinion values ( Figure  5a ). The DCA results were usually higher than the Afinion values; except in the last 6 months of our study, the DCA measurements fell below the Afinion results, and as much as 0.6% lower than the Biorad values. Both POC techniques gave systematically lower values than the Tosoh measurements ( Figure 5b) .
We graphed the published bias values for the 2 POC and the 2 central lab techniques. During the 3-year time period of our study, the reported bias values for the DCA and the Afinion techniques were quite variable ( Figure 6 ). The Afinion values for the low and midrange HbA1c samples were always within 0.1% of the NGSP reference, but the high range samples went from as low as 0.4% less than the acceptable range at the beginning of our study to a positive value at the end. During the same period, the DCA comparisons to the CAP sample results from the NGSP varied from as much as 0.15% higher for the midrange samples to 0.25% lower. However, in the last period of our comparison, the DCA results for all samples were uniformly lower than the CAP sample results, consistent with the drop in HbA1c values we observed in our comparison with the Afinion and 2 central lab procedures. This significant variability in bias results was not, however, limited to the POC techniques. The 2 central laboratory techniques also showed highly variable bias levels. The Tosoh bias was uniformly and systematically elevated, but, even so, the values were not consistent. At certain time points, the Tosoh HbA1c values for all 3 NGSP levels were as much as 0.4% higher than the reference techniques. The bias from the NGSP values for the Biorad technique were not as great but were less uniform than the Tosoh comparison and were quite variable over time. During the initial period of our comparisons, the Biorad bias was as high as 0.25% positive for all levels. Later, the Biorad bias became negative before rising again toward the end of our study ( Figure 6 ).
Discussion
POC HbA1c testing has become essential to management of diabetes patients in clinical practices as a quantitative index of the success of treatment. Given the importance of HbA1c measurement, it is imperative that the values be reliable, validated and controlled. The NGSP has worked with the College of American Pathologists to tighten proficiency-testing requirements. As a result of these efforts, variability of HbA1c results among clinical laboratories has been considerably reduced. In 2014, the requirement for certification of the many different techniques used clinically is that values fall within ±6% of the reference standard values. Although the elaborate NGSP standardization procedures have been successful in reducing bias, this is still fairly large tolerance. From the viewpoint of a practicing physician, the most significant clinical measure is not the value at any given time point but, rather, the change in HbA1c as a result of diabetes management over time. Although various techniques may provide different absolute results, these differences should not affect treatment decisions, provided that one maintains a single assay technique with consistent and reproducible results over time. Our goal was to determine the longitudinal performance of POC testing of HbA1c. We chose to compare the POC results for the 2 techniques considered most reliable to 2 frequently utilized central laboratory procedures.
We found that there was significant variability in the values obtained over time. This variability was evident in comparing the 2 techniques to one another and to the 2 central lab procedures. Furthermore, the variability was corroborated by comparisons performed by the NGSP reference laboratories performed and reported independently by the CAP procedures, and the bias values were different for the low, midrange, and high values of the NGSP standards. However, we found that the 2 central lab procedures also showed significant bias values as compared to the NGSP controls. In fact, the Tosoh HPLC procedure gave systematically elevated results for all control levels throughout our observation period. The Biorad bias values wandered from positive to negative, and then the high range control returned to a high positive bias value at the end of our comparison period.
Our study is the longest duration comparison of HbA1c assay techniques to date. In a 10 month study, 121 young persons with Type 1 diabetes from 4 centers provided 450 paired samples for POC HbA1c and central laboratory-based HPLC HbA1c determinations. 30 The 450 paired samples (median of 4 pairs/patient) were highly correlated (r = .97, P < .0001), as were time-specific and site-specific pairs (r = .94 to .98, P < .0001), but, as we have shown, correlation is not a sufficient criterion for evaluation of clinical validity. There was no assessment of bias of the 2 assays versus CAP PT (proficiency test) samples during the time period of the study.
We have now demonstrated that the 2 POC assays which are considered most reliable show significant differences in measured values which are variable over time. It would be easy to conclude that these assays are not as useful as standard central laboratory techniques were it not for the similarly variable bias results shown by the central lab methods with relation to the CAP PT samples over the same time course.
Conclusions
From the real world aspect of clinical practice, it is essential to closely monitor HbA1c values over time in relation to external standards. Reliance on controls supplied in assay kits is not sufficient to eliminate lot to lot variation. The estimates of bias obtained from the CAP-NGSP surveys are useful, but the tolerances to variation are large with respect to clinically meaningful change. The NGSP requires that the mean of the differences between an individual network laboratory and the CPRL must not exceed 0.35%, but an absolute value difference of 0.35% can translate to a worst case difference of ±0.7%. The basis for certification of manufacturer data is that 37 of 40 results for samples must fall within ± 6% of the secondary reference laboratory result for the samples. This margin of error could potentially be as large as 6% of a HbA1c value of 10%, thus a plus or minus range of 0.6%. It may be argued that, at such high levels, one can safely conclude that diabetes is poorly controlled and that the potential error is clinically insignificant. Conversely, if one accepts the American Diabetes Association target of 7% for control of diabetes, the error could be as great as 0.42%. For diagnosis of diabetes based on the arbitrarily chosen value of 6.5%, the difference in values could reach 0.39%. While this argument is based on a worst case scenario, it suggests caution in total reliance on HbA1c as a monitor of adequacy of diabetes control.
We routinely measure HbA1c with both the Afinion and the DCA Vantage in our clinical practice, also utilizing external assays for comparison on a routine basis to educate ourselves as to potential changes over time. Such an approach may be criticized as overkill and is clearly not cost effective. Yet, it is important that all those who rely on POC methods and, as we have seen, on central laboratory measurement as well, understand the potential limitations of these assays. However, in the United States, clinical offices using POC HbA1c are "waived" sites and are not required to participate in external proficiency testing. It is essential to be able to validate that a procedure accurately reflects clinically relevant results at any given point in time. One cannot be lulled into over confidence by results falling within periodic controls. In fact, as our results show, not even satisfactory results on various proficiency tests guarantee clinical invariance of values over time since there is a drift both upward and downward over the course of time. The assessment of diabetes control should proceed from the evaluation of HbA1c coupled with review of plasma glucose and of self-monitored blood glucose values. The clinician should be willing to question divergence of the assessments arising from comparison of HbA1c to glucose values as compared to HbA1c.
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